Patients with liver cirrhosis had significantly reduced α-defensin 5 and 6 expression in gut crypts, strongly correlating with elevated blood endotoxin levels — suggesting antimicrobial peptide loss contributes to the gut barrier failure seen in cirrhosis.
r = -0.79 correlationbetween α-defensin HD5 expression and serum endotoxin levels in cirrhosis patients, linking antimicrobial peptide loss to bacterial translocation
What the researchers found
Cirrhotic patients (n=67) showed diminished HD5 and HD6 expression compared to healthy controls (n=27; p=0.000287 and p=0.000314 respectively). Decompensated cirrhosis patients (n=40) had even lower defensin expression than compensated patients (n=27; p=0.025 and p=0.041). Cirrhotic patients had significantly higher serum endotoxin levels (p<0.0001).
HD5 and HD6 expression showed strong inverse correlations with endotoxin levels (r=-0.790 and r=-0.777, both p<0.0001). Intraepithelial T-lymphocytes were decreased in decompensated cirrhosis versus controls (p=0.002), but B-lymphocyte infiltrates did not differ between groups.
Why it matters
Bacterial translocation (bacteria leaking from the gut into the bloodstream) is a major cause of infection and death in cirrhosis patients. Understanding that antimicrobial peptide depletion underlies this gut barrier failure opens new therapeutic avenues — potentially boosting defensin expression could prevent infections without relying solely on antibiotics, which risk resistance.
How the study worked
Prospective study of 40 patients with decompensated cirrhosis, 27 with compensated cirrhosis, and 27 healthy controls. All underwent duodenal biopsy. HD5 and HD6 expression in intestinal crypts was evaluated by immunohistochemistry and immunofluorescence. Serum endotoxin was quantified. Intraepithelial T-lymphocytes and lamina propria B-lymphocytes were counted.
What this study cannot tell us
The study is cross-sectional, so it cannot determine whether defensin loss causes gut barrier dysfunction or results from it. The biopsy location (duodenum) may not represent the entire intestinal barrier. The mechanism by which cirrhosis reduces defensin expression was not investigated. Sample sizes, while reasonable, are modest for subgroup analyses.
How to read the evidence
This is a prospective clinical study with 94 participants, duodenal biopsies, and well-defined control groups. The strong correlations and highly significant p-values strengthen the findings, though the cross-sectional design limits causal inference.
When this study was published
Published in 2018, this study contributes to the understanding of the gut-liver axis and antimicrobial peptide biology in cirrhosis, an area of ongoing research.
The bigger picture
This study connects antimicrobial peptide biology with liver disease, showing that the gut's first line of defense — Paneth cell defensins — fails in cirrhosis. This adds to understanding of the gut-liver axis, where gut barrier integrity directly impacts liver disease outcomes. The finding could have implications beyond cirrhosis for any condition where gut barrier function is compromised.
Questions still open
- Could therapeutic restoration of α-defensin levels prevent bacterial translocation and infections in cirrhosis?
- What mechanism causes cirrhosis to reduce Paneth cell defensin production?
- Would defensin levels serve as a biomarker for gut barrier dysfunction severity in liver disease?
Common questions
What are α-defensins and why do they matter in liver disease?
Could boosting defensin levels help cirrhosis patients?
Read the original research
Expression of α-Defensins, CD20+ B-lymphocytes, and Intraepithelial CD3+ T-lymphocytes in the Intestinal Mucosa of Patients with Liver Cirrhosis: Emerging Mediators of Intestinal Barrier Function.
Digestive diseases and sciences, 63(10), 2582-2592
Citation
Tsiaoussis, Georgios I; Papaioannou, Eleni C; Kourea, Eleni P; Assimakopoulos, Stelios F; Theocharis, Georgios I; Petropoulos, Michalis; Theopistos, Vasileios I; Diamantopoulou, Georgia G; Lygerou, Zoi; Spiliopoulou, Iris; Thomopoulos, Konstantinos C. (2018). Expression of α-Defensins, CD20+ B-lymphocytes, and Intraepithelial CD3+ T-lymphocytes in the Intestinal Mucosa of Patients with Liver Cirrhosis: Emerging Mediators of Intestinal Barrier Function.. Digestive diseases and sciences, 63(10), 2582-2592. https://doi.org/10.1007/s10620-018-5146-9